ArticleEpilepsia2022
Drivers of US health care spending for persons with seizures and/or epilepsies, 2010-2018.
Article in Epilepsia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- People Powering Change: The Movement for a National Plan for Epilepsy.Epilepsy currents · 2026Review
- Article
- Current review on inducible nitric oxide synthase and Src tyrosine kinase inhibitors as disease-modifiers in preclinical models of epilepsy.Histology and histopathology · 2026Review
- Trends in paediatric antiseizure-medication use and costs in France, 2014-2023: a nationwide population-based analysis.The Lancet regional health. Europe · 2026Article
- Development and Validation of an Administrative Algorithm to Identify Veterans With Epilepsy.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Dietary Antioxidant Quality Score and Epilepsy Odds in the US Adults: A Cross-Sectional NHANES Study.Brain and behavior · 2025Article
- Characterizing the burden of healthcare utilization and expenditure for epilepsy and unclassified seizures in the U.S., 2016-2022.Epilepsia open · 2025Article
- Achieving epilepsy care for all: Ecosystem-based transformation.Epilepsia · 2025Review
- Characterizing emergency department and inpatient health care utilization after seizure-related hospitalization: A retrospective cohort study.Epilepsia · 2024Article
- Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations.Advances in therapy · 2023Review
- Epilepsy-Related Direct Medical and Direct Non-Medical Cost in Adult Patients Living with Epilepsy at a Tertiary Neurology Center in Rwanda.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications.Neuropsychiatric disease and treatment · 2022Review
- Money Matters: Measuring the Economic Impact of Epilepsy.Epilepsy currentsArticle
- Brand Name Versus Generic?Epilepsy currentsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study was undertaken to characterize spending for persons classified with seizure or epilepsy and to determine whether spending has increased over time.
methodsIn this cross-sectional study, we pooled data from the Medical Expenditure Panel Survey (MEPS) household component files for 2010-2018. We matched cases to controls on age and sex of a population-based sample of MEPS respondents (community-dwelling persons of all ages) with records associated with a medical event (e.g., outpatient visit, hospital inpatient) for seizure, epilepsy, or both. Outcomes were weighted to be representative of the civilian, noninstitutionalized population. We estimated the treated prevalence of epilepsy and seizure, health care spending overall and by site of care, and trends in spending growth.
resultsWe identified 1078 epilepsy cases and 2344 seizure cases. Treated prevalence was .38% (95% confidence interval [CI] = .34-.41) for epilepsy, .76% (95% CI = .71-.81) for seizure, and 1.14% (95% CI = 1.08-1.20) for epilepsy or seizure. The difference in annual spending for cases compared to controls was $4580 (95% CI = $3362-$5798) for epilepsy, $7935 (95% CI, $6237-$9634) for seizure, and $6853 (95% CI = $5623-$8084) for epilepsy or seizure, translating into aggregate costs of $5.4 billion, $19.0 billion, and $24.5 billion. From 2010 to 2018, the annual growth rate in total spending incurred for seizures and/or epilepsies was 7.6% compared to 3.6% among controls. SIGNIFICANCE: US economic burden of seizures and/or epilepsies is substantial and warrants interventions focused on their unique and overlapping causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.